Surgical Margin — The Border of Removed Tissue

When a surgeon resects a solid tumour, they intentionally remove an extra envelope of adjacent normal tissue to ensure complete eradication. Once excised, the specimen is sent to pathology, where its outer edges are coated with coloured surgical inks. The pathologist slices the tissue and examines it microscopically to assess the distance between the outermost cancer cells and the inked border.

The findings are classified into three main categories: negative (or clear), meaning no cancer cells reach the inked edge; positive, meaning cancer cells touch the cut surface; and close, meaning tumour cells sit within a few millimetres of the boundary, varying by clinical guideline.

Surgical margin status is a primary determinant of whether further local treatment is required. A clear margin substantially lowers the likelihood that cancer will recur in the same operative area. Understanding your margin results helps you navigate discussions about whether a second operation (re-excision) is advisable, or whether adjuvant treatments like radiotherapy must be intensified to ensure local control.

Margin status is tested exclusively via histopathological examination. After surgery, the specimen is inked, fixed in formalin, and processed into thin microscopic slides. During certain operations, intraoperative frozen sections or specimen radiography are used to provide immediate, preliminary margin assessments while the patient remains in theatre.

Margins are evaluated in nearly all solid tumour operations. They are particularly critical in breast-conserving surgery, melanoma and non-melanoma skin cancer removals, colorectal resections, soft tissue sarcomas, and head and neck tumours, where sparing healthy surrounding anatomy is equally paramount.

A clear margin usually confirms that local surgical goals have been met. A positive or close margin often prompts a recommendation for further surgery to remove more tissue from the surgical bed. If repeat surgery is not technically feasible or safe, oncologists typically recommend adjuvant radiotherapy to destroy any residual microscopic disease.